Journal: Cells

Article Title: Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers

doi: 10.3390/cells10050978

Figure Lengend Snippet: Binding of Ad5/3 oncolytic adenoviruses to clinically relevant human ovarian cancer TILs. Human ovarian cancer TILs were washed, incubated for 30 min with ( A ) Ad5/3-Luc1, ( B ) Ad5/3-E2F-D24-hTNFa, ( C ) Ad5/3-E2F-D24-hIL2 and ( D ) TILT-123, and washed up to five times by centrifugation. DNA was extracted from pellets and supernatants after every wash and analyzed for the presence of virus DNA copies (E4). Data is presented as mean + SEM.

Article Snippet: To evaluate the antitumor efficacy of TILs loaded with TILT-123 in non-injected tumors, we implanted immunocompromised NOD.Cg- Prkdc scid - Il2rg tm1Sug /JicTac (Taconic) with 4 × 10 6 HapT1 cells in both left and right lower flanks.

Techniques: Binding Assay, Incubation, Centrifugation

Journal: Cells

Article Title: Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers

doi: 10.3390/cells10050978

Figure Lengend Snippet: Binding of TILT-123 to hamster TILs, virus copy numbers in HapT1 tumors and antitumor efficacy in hamster tumors. ( A ) After expansion, hamster TILs were washed, incubated for 30 min with TILT-123 and washed up to five times. DNA was extracted from pellets and supernatants after every wash and analyzed for the presence of virus DNA copies (E4); ( B , C ) hamsters bearing bilateral HapT1 tumors were treated with i.t. injections of TILT-123 or PBS and i.p. injected with TILs loaded with TILT-123 [TILs(TILT-123)], TILT-123 or RPMI. DNA was extracted from ( B ) day 3 or ( C ) day 5 snap-frozen tumors and analyzed for the presence of virus DNA copies (E1A). The virus copy numbers were normalized to the amount of genomic DNA in the samples (GAPDH expression); hamsters bearing bilateral HapT1 tumors were treated with i.t. injections of TILT-123 or PBS and i.p. injected with TILs loaded with TILT-123 [TILs(TILT-123)], TILT-123 or RPMI. Tumors were measured with an electronic caliper on days 3 ( D ) and 5 ( E ). Normalized tumor volume data was obtained by normalizing the daily tumor volume with day 0 tumor volumes. Statistically significant differences in ( C ) were assessed using Kruskal Wallis test with Dunn’s multiple comparison test while in ( B ) were assessed using unpaired Student’s t test with Welsh’s correction. No statistically significant differences were found among the groups by using one-way ANOVA with Tukey’s multiple comparison test in ( D , E ). Only statistically significant differences are shown. Data is presented as mean + SEM; A—animal, T—tumor. *— p < 0.05.

Article Snippet: To evaluate the antitumor efficacy of TILs loaded with TILT-123 in non-injected tumors, we implanted immunocompromised NOD.Cg- Prkdc scid - Il2rg tm1Sug /JicTac (Taconic) with 4 × 10 6 HapT1 cells in both left and right lower flanks.

Techniques: Binding Assay, Incubation, Injection, Expressing

Journal: Cells

Article Title: Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers

doi: 10.3390/cells10050978

Figure Lengend Snippet: Biodistribution of virus following treatment. Immunocompromised NOG mice bearing bilateral HapT1 tumors were treated with i.t. injections of TILT-123 or PBS and i.v. injected with hamster TILs loaded with TILT-123 [TILs(TILT-123)], TILT-123, or PBS. DNA was extracted from day 4 snap-frozen ( A ) tumors and ( B ) livers and analyzed for the presence of virus DNA copies (E1A). The virus copy numbers were normalized to the amount of genomic DNA in the samples (GAPDH expression). ( C ) Tumors were collected, processed, and analyzed by flow cytometry for CD4 and CD8 positive cells. Dashed lines indicate the highest average background in control groups for CD8+ and CD4+ cells. Statistically significant differences were found by performing Kruskal Wallis test with Dunn’s multiple comparison test. Only statistically significant differences are shown. Data is presented as mean + SEM; A—animal, T—tumor. *— p < 0.05.

Article Snippet: To evaluate the antitumor efficacy of TILs loaded with TILT-123 in non-injected tumors, we implanted immunocompromised NOD.Cg- Prkdc scid - Il2rg tm1Sug /JicTac (Taconic) with 4 × 10 6 HapT1 cells in both left and right lower flanks.

Techniques: Injection, Expressing, Flow Cytometry

Journal: Cells

Article Title: Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers

doi: 10.3390/cells10050978

Figure Lengend Snippet: Antitumor efficacy following treatment with hamster TILs loaded with TILT-123. Immunocompromised NOG mice bearing bilateral HapT1 tumors were treated with i.t. injections of TILT-123 or PBS and i.v. injected with TILs loaded with TILT-123 TILs(TILT-123) 1:500 TILs:VP, TILT-123, or PBS once a week. ( A ) Growth of injected tumors over 11 days. Data is presented as median absolute tumor volume (cm 3 ); ( B ) growth of injected tumors normalized to PBS control group’s tumor volumes from days 8–11, which means that PBS tumor volumes are set as 100%. ( C ) Growth of non-injected tumors over 11 days. Data is presented as median absolute tumor volume (cm 3 ); ( D ) growth of injected tumors normalized to PBS control group’s tumor volumes from days 8–11. Statistically significant differences in ( B , D ) were found by performing linear mixed model test in log-transformed PBS-normalized tumor volumes. Only statistically significant differences are shown. Data in ( B , D ) is presented as mean + SEM. *— p < 0.05.

Article Snippet: To evaluate the antitumor efficacy of TILs loaded with TILT-123 in non-injected tumors, we implanted immunocompromised NOD.Cg- Prkdc scid - Il2rg tm1Sug /JicTac (Taconic) with 4 × 10 6 HapT1 cells in both left and right lower flanks.

Techniques: Injection, Transformation Assay

Journal: Signal Transduction and Targeted Therapy

Article Title: Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

doi: 10.1038/s41392-022-00951-x

Figure Lengend Snippet: Ongoing or completed clinical trials with OVs encoding immunostimulatory transgenes

Article Snippet: , TILT-123 (TILT Biotherapeutics) , TNF-α and IL-2 , Solid tumor , NCT04695327 , Phase I Recruiting.

Techniques: Clinical Proteomics, Wilms Tumor Assay